Jahnavi¹*, Shantanu Tandon² and Honey Ashok³

¹Postgraduate, Department of ENT and Head and Neck Surgery, Sakra World Hospital, Devarabeesinahalli, Bangalore, Karnataka, India
²Fellowship Laryngology, Senior Consultant, Department of ENT and Head and Neck Surgery, Sakra World Hospital, Devarabeesinahalli, Bangalore, Karnataka, India
³Fellowship Head and Neck Surgery, HOD, Senior Consultant, Department of ENT and Head and Neck Surgery, Sakra World Hospital, Devarabeesinahalli, Bangalore, Karnataka, India

*Corresponding Author: Jahnavi, Postgraduate, Department of ENT and Head and Neck Surgery, Sakra World Hospital, Devarabeesinahalli, Bangalore, Karnataka, India.

Received: July 18, 2022; Published: July 26, 2022

Abstract

The new coronavirus disease 2019 (Covid-19) is a highly contagious viral infection resulting from the SARS-CoV-2 (severe acute respiratory syndrome - covid virus - 2) infection, which is transmitted from human to human by respiratory secretions. This virus, belonging to the coronavirus family, can result in various clinical presentations of the disease, from common rhinorrhoea to severe acute respiratory syndrome.

This study was conducted in covid positive patients admitted in Sakra World Hospital, Bangalore, a tertiary care centre. This paper reviews the olfactory physiology and summarizes the clinical reports of anosmia and hyposmia in this current viral outbreak, specifically aimed at identifying if anosmia/hyposmia is one of the major indicating symptom of covid infection and to examine the possible role of olfactory disturbances as a screening diagnostic tool in mildly symptomatic patients.

The study was conducted on 200 patients with a positive RTPCR (Reverese transcriptase polymerase chain reaction) for Covid and admitted in our hospital, each patient was assessed with a subjective DynaCHRON questionnaire and then underwent objective Indian smell identification test to identify odor discrimination and odor threshold. The data regards the prevalence of hyposmia and anosmia along with the prevalence of isolated olfactory dysfunction and was found that hyposmia [58.50%] was more prevalent than anosmia [7.50%]. Olfactory dysfunction is severe in grade [28.50] and isolated olfactory dysfunction was seen in 20.50%, which is statistically significant with p value p < 0.0001.

We conclude that the olfactory dysfunction is one of the common symptom in Covid 19 infected patients with moderate to severe degree of loss and the objective smell test can be a helpful screening tool in diagnosing the early phase of the disease.

Keywords: COVID 19; Olfactory Dysfunction; Hyposmia; Anosmia

References

1. Brann DH., et al. “Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia”. Science Advances31 (2020): eabc5801.
2. Mishra P., et al. “Prevalence of New Onset Anosmia in COVID-19 Patients: Is the Trend Different Between European and Indian Population?” Indian Journal of Otolaryngology and Head and Neck Surgery 4 (2020): 1-4.
3. Attems J., et al. “Olfactory bulb involvement in neurodegenerative diseases”. Acta Neuropathology 127 (2014): 459-475.
4. Richard L Doty and Steven M Bromley. “Abnormalities of Smell”. Chapter 110, Scott Brown‘s Otorhinolaryngology and Head and Neck Surgery, John C. Watkinson, Raymond W. Clarke (eds.), Volume 1, 8^th edition, CRC Press, Taylor and Francis Group, New York (2018): 1227-1241.
5. Diodato A., et al. “Molecular signatures of neural connectivity in the olfactory cortex”. Nature Communication 7 (2016): 12238.
6. Richard L Doty and Alexis H Jackman. “Olfaction and Gustation”. Chapter 38, Ballenger‘s Otorhinolaryngology Head and Neck Surgery, James B. Snow Jr, P. Ashley Wackym. BC Decker inc (eds), 17^th edition, People‘s Medical Publishing house Shelton, Connecticut (2009): 465-479.
7. Wiersinga WJ., et al. “Pathophysiology, Transmission, Diagnosis, and Treatment of Coronavirus Disease 2019 (COVID-19): A Review”. JAMA 8 (2020): 782-793.
8. Mao L., et al. “Neurologic Manifestations of Hospitalized Patients with Coronavirus Disease 2019 in Wuhan, China”. JAMA Neurology6 (2020): 683-690.
9. Li YC., et al. “The neuroinvasive potential of SARS-CoV2 may play a role in the respiratory failure of COVID-19 patients”. Journal of Medical Virology6 (2020): 552-555.
10. Hoffmann M., et al. “SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor”. Cell 2 (2020): 271-280.
11. Sungnak W., et al. “HCA Lung Biological Network. SARSCoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes”. Nature Medicine5 (2020): 681-687.
12. Kacha S., et al. “Development and validity of the DyNaChron questionnaire for chronic nasal dysfunction”. European Archives of Oto-Rhino-Laryngology 1 (2021): 143-153.

Citation

Citation: Jahnavi., et al. “Subjective and Objective Analysis of Prevalence of Anosmia and Hyposmia in Covid 19 Infected Patients in a Tertiary Care Centre - A Cross-sectional Study".Acta Scientific Otolaryngology 4.8 (2022): 50-55 .

Copyright

Copyright: © 2022 Jahnavi., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.